Success Metrics

Active Trials
11(100%)

Phase Distribution

Ph phase_2
8
73%
Ph phase_1
3
27%

Phase Distribution

3

Early Stage

8

Mid Stage

0

Late Stage

Phase Distribution11 total trials
Phase 1Safety & dosage
3(27.3%)
Phase 2Efficacy & side effects
8(72.7%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

11

trials recruiting

Total Trials

11

all time

Status Distribution
Active(11)

Detailed Status

Recruiting10
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
11
Active
11
Success Rate
N/A
Most Advanced
Phase 2

Trials by Phase

Phase 13 (27.3%)
Phase 28 (72.7%)

Trials by Status

active_not_recruiting19%
recruiting1091%

Recent Activity

11 active trials
Showing 5 of 11
recruitingphase_2

A Study of SI-B001+SI-B003 Combined With Platinum-based Chemotherapy as First-line Treatment in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

NCT06668961
recruitingphase_2

A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Cervical Cancer and Other Gynecological Malignancies

NCT05990803
active_not_recruitingphase_1

A Study of SI-B003, a PD-1/CTLA-4 Bispecific Antibody, in Patients With Advanced Solid Tumors

NCT04606472
recruitingphase_2

A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Extensive Stage Small Cell Lung Cancer

NCT05924841
recruitingphase_2

A Study of SI-B003 or BL-B01D1+SI-B003 in Patients With Unresectable Locally Advanced or Recurrent Metastatic HER2 Negative Breast Cancer

NCT06042894
View all 11 trials

Clinical Trials (11)

Showing 11 of 11 trials
NCT06668961Phase 2

A Study of SI-B001+SI-B003 Combined With Platinum-based Chemotherapy as First-line Treatment in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Recruiting
NCT05990803Phase 2

A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Cervical Cancer and Other Gynecological Malignancies

Recruiting
NCT04606472Phase 1

A Study of SI-B003, a PD-1/CTLA-4 Bispecific Antibody, in Patients With Advanced Solid Tumors

Active Not Recruiting
NCT05924841Phase 2

A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Extensive Stage Small Cell Lung Cancer

Recruiting
NCT06042894Phase 2

A Study of SI-B003 or BL-B01D1+SI-B003 in Patients With Unresectable Locally Advanced or Recurrent Metastatic HER2 Negative Breast Cancer

Recruiting
NCT05956587Phase 2

A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors

Recruiting
NCT05668858Phase 1

A Study of SI-B001+SI-B003± Chemotherapy in Patients With Locally Advanced or Metastatic Head and Neck Squamous Cell Carcinoma

Recruiting
NCT06006169Phase 2

A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors

Recruiting
NCT05965856Phase 2

A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma and Other Solid Tumors

Recruiting
NCT06008054Phase 2

A Study of SI-B003, BL-B01D1+SI-B003 and BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Esophageal Cancer, Gastric Cancer, Colorectal Cancer and Other Gastrointestinal Tumors

Recruiting
NCT05949606Phase 1

A Study of SI-B001+SI-B003± Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer

Recruiting

All 11 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
11